W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > August 2012

RE: seeks input on Study Data Exchange Standards

From: Lin MD, Simon <LINMD.SIMON@mcrf.mfldclin.edu>
Date: Wed, 15 Aug 2012 15:11:46 +0000
To: "Mead, Charlie (NIH/NCI) [C]" <meadch@mail.nih.gov>, Kerstin Forsberg <kerstin.l.forsberg@gmail.com>, HCLS hcls <public-semweb-lifesci@w3.org>
Message-ID: <A5BD550FC766564987DA2A59779890303DFD198D@MCL-EXMB02.mfldclin.org>
Great topic! I can imagine a potential white paper from this group. 

Besides technology, factors to consider might include: flexibility, implementation cost, return on investments, path to migration etc.

Best regards,

Simon

==================================================
Simon Lin, MD
Director, Biomedical Informatics Research Center 
Marshfield Clinic Research Foundation 
1000 N Oak Ave, Marshfield, WI 54449 
Office 715-221-7299 
Lin.Simon@mcrf.mfldclin.edu 
www.marshfieldclinic.org/birc

For scheduling assistance, please contact
      Crystal Gumz, Administrative Secretary
      gumz.crystal@mcrf.mfldclin.edu
      715-221-6403


-----Original Message-----
From: Mead, Charlie (NIH/NCI) [C] [mailto:meadch@mail.nih.gov] 
Sent: Wednesday, August 15, 2012 1:02 AM
To: Kerstin Forsberg; HCLS hcls
Subject: RE: seeks input on Study Data Exchange Standards

I would say Yes -- particularly since there is now an effort to represent some of newest HL7 standards -- FHIR resource definitions in particular -- using SW approaches...and the BRIDG OWL representation will almost certainly benefit from this effort.

charlie
________________________________________
From: Kerstin Forsberg [kerstin.l.forsberg@gmail.com]
Sent: Wednesday, August 15, 2012 1:57 AM
To: HCLS hcls
Subject: FDA: seeks input on Study Data Exchange Standards

FDA seeks "input from industry, technology vendors, and other members of the public regarding the advantages and disadvantages of current and emerging open, consensus-based standards for the exchange of regulated study data. "

In the annoncement for a meeting 5 November FDA ask for responses, before 5 October, on questions such as "- What are the advantages and disadvantages of HL7 v3 and CDISC ODM?"

And, interestingly, they also ask: "- Are there other open data exchange standards that should be evaluated?"

Is this an opportunity for a semantic web based proposal?

Kind Regards

Kerstin Forsberg

AstraZeneca



https://www.federalregister.gov/articles/2012/08/14/2012-19748/regulatory-new-drug-review-solutions-for-study-data-exchange-standards-notice-of-meeting-request-for

______________________________________________________________________
The contents of this message may contain private, protected and/or privileged information.  If you received this message in error, you should destroy the e-mail message and any attachments or copies, and you are prohibited from retaining, distributing, disclosing or using any information contained within.  Please contact the sender and advise of the erroneous delivery by return e-mail or telephone.  Thank you for your cooperation.
Received on Wednesday, 15 August 2012 15:12:19 GMT

This archive was generated by hypermail 2.3.1 : Tuesday, 26 March 2013 18:01:12 GMT